Stockscreener 앱 받기
38.87
2.73%
-1.09
전일 마감가:
$39.96
열려 있는:
$40.02
하루 거래량:
1.29M
Relative Volume:
1.18
시가총액:
$3.10B
수익:
-
순이익/손실:
$-237.22M
주가수익비율:
-10.28
EPS:
-3.78
순현금흐름:
$-212.64M
1주 성능:
-2.46%
1개월 성능:
+3.82%
6개월 성능:
+38.38%
1년 성능:
+87.51%
1일 변동 폭
$38.73
$40.50
1주일 범위
$37.28
$42.18
52주 변동 폭
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
명칭
Akero Therapeutics Inc
전화
650-487-6488
주소
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
38.87 | 3.18B | 0 | -237.22M | -212.64M | -3.78 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-18 | 개시 | Citigroup | Buy |
| 2024-04-22 | 재개 | BofA Securities | Neutral |
| 2023-09-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 개시 | UBS | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 개시 | Guggenheim | Buy |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-07-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-02 | 개시 | H.C. Wainwright | Buy |
| 2020-02-10 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Evercore ISI | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
| 2019-07-15 | 개시 | Jefferies | Buy |
| 2019-07-15 | 개시 | ROTH Capital | Buy |
모두보기
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
30,208 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Cubist Systematic Strategies LLC - MarketBeat
Northern Trust Corp Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by MPM Bioimpact LLC - MarketBeat
Algert Global LLC Lowers Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Orbimed Advisors LLC Makes New $1.84 Million Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Holdings Trimmed by Janus Henderson Group PLC - MarketBeat
Dimensional Fund Advisors LP Grows Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
The Manufacturers Life Insurance Company Has $3.47 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Lessened by Fred Alger Management LLC - MarketBeat
Citigroup Issues Pessimistic Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price - Defense World
Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Beats Estimates By $1.91 EPS - MarketBeat
Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target - TipRanks
Insider Sell: Akero Therapeutics Inc (AKRO) President and CEO An - GuruFocus
Balyasny Asset Management L.P. Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Pfizer Dissolves Share Stake In Akero Therapeutics - marketscreener.com
Akero Therapeutics (AKRO): Citigroup Adjusts Price Target, Maintains Buy Rating | AKRO Stock News - GuruFocus
Jefferies maintains Buy on Akero stock, reiterates $75 target - Investing.com
Citi Adjusts Price Target for Akero Therapeutics (AKRO) Amid Tri - GuruFocus
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Best Biotech Stocks to Buy in 2025 - TradingView
AKRO: Promising Results from Phase 2b SYMMETRY Study with EFX | - GuruFocus
Decoding Akero Therapeutics Inc (AKRO): A Strategic SWOT Insight - GuruFocus
Deep Track Capital LP Acquires 800,216 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Morgan Stanley cuts Akero stock price target to $84 from $90 - Investing.com UK
Akero Therapeutics (AKRO) Price Target Lowered by Morgan Stanley - GuruFocus
Akero Therapeutics Q1 Operating Expenses USD 80.9 Million - marketscreener.com
Akero Therapeutics, Inc. SEC 10-Q Report - TradingView
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Cutter Capital Management LP Invests $6.40 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Akero Therapeutics (AKRO) Reveals Positive Results from EFX Tria - GuruFocus
Akero Therapeutics (AKRO) Reveals Positive Results from EFX Trial at EASL Congress | AKRO Stock News - GuruFocus
2025-05-11 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation | NDAQ:AKRO | Press Release - Stockhouse
Hsbc Holdings PLC Acquires 621 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL - GlobeNewswire Inc.
Akero Therapeutics und HistoIndex präsentieren neue - GlobeNewswire
Susquehanna Fundamental Investments LLC Purchases New Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Akero Therapeutics Stock: Breakthrough Data Strengthens Market Position - sharewise
Akero Therapeutics Reveals AI-Based Analysis Supporting Efruxifermin's Antifibrotic Activity in Phase 2b HARMONY Trial for Pre-Cirrhotic MASH - Nasdaq
Akero Therapeutics and HistoIndex Present New Analyses of - GlobeNewswire
Akero Therapeutics, Inc. and HistoIndex Present New Analyses of Phase 2b Harmony Trial in Oral and Poster Presentations at the EASL Congress 2025 - marketscreener.com
Long Term Trading Analysis for (AKRO) - news.stocktradersdaily.com
Dimensional Fund Advisors LP Boosts Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics (NASDAQ:AKRO) Trading Down 6% After Insider Selling - Defense World
Renaissance Technologies LLC Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero reports promising cirrhosis treatment trial results By Investing.com - Investing.com India
Akero reports promising cirrhosis treatment trial results - Investing.com Australia
Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug - marketscreener.com
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine - GlobeNewswire
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 - The Manila Times
Akero Therapeutics Inc (AKRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Akero Therapeutics Inc 주식 (AKRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cheng Andrew | President and CEO |
May 12 '25 |
Sale |
41.48 |
30,000 |
1,244,455 |
594,324 |
1.54%
7.58%
자본화:
|
볼륨(24시간):